Press Releases
View printer-friendly version << Back
Avadel Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Results
To access the conference call, investors are invited to dial (844) 388-0559 (U.S. and
About
Safe Harbor: This press release contains forward-looking statements, including, but not limited to, statements related to Avadel’s business strategy and development plans, expected net sales growth of its marketed products, expected financial performance in future periods, expected timing of clinical, regulatory and commercial events, including those relating to the Phase 3 clinical trial of FT 218, potential market opportunity and estimated peak sales for Avadel’s approved medicines and pipeline candidates, potential growth of Avadel’s medicines, expected impact of the Tax Cut and Jobs Act, and business and other statements that are not historical facts. These forward-looking statements are based on Avadel’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks that Avadel’s actual future financial and operating results may differ from its expectations or goals; Avadel’s ability to grow net sales from existing products; the availability of coverage and adequate reimbursement and pricing from government and third-party payers and risks relating to Avadel’s ability to successfully implement its business strategies; risks associated with drug development and regulatory approvals; potential delays in clinical trials, including due to enrollment rates or adverse events; risks that results from on-going or future clinical trials may be inconsistent with results from prior pre-clinical studies or clinical trials; risks in the ability to recruit, train and retain qualified personnel; competition, including potential generic competition; the ability to protect intellectual property and defend patents; regulatory obligations and oversight, including any changes in the legal and regulatory environment in which Avadel operates and those risks detailed from time-to-time under the caption “Risk Factors” and elsewhere in Avadel’s filings and reports with the
Contacts:
Chief Financial Officer
Phone: (636) 449-1844
E-mail: mkanan@avadel.com
Sr. Director, Investor Relations and Corporate Communications
Phone: (636) 449-5866
Email: lstival@avadel.com